📣 Help Shape the Future of UKRI's Gateway to Research (GtR)

We're improving UKRI's Gateway to Research and are seeking your input! If you would be interested in being interviewed about the improvements we're making and to have your say about how we can make GtR more user-friendly, impactful, and effective for the Research and Innovation community, please email gateway@ukri.org.

Type 2 myocardial infarction and myocardial injury: eligibility for novel medical therapy to derisk clinical trials. (2021)

First Author: Sykes R

Attributed to: MICA: A Developmental Trial of Personalised Medicine for Repurposing Zibotentan, a Selective Endothelin A Receptor Blocker, in Microvascular Angina. funded by MRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1136/openhrt-2021-001633

PubMed Identifier: 34083388

Publication URI: http://europepmc.org/abstract/MED/34083388

Type: Journal Article/Review

Volume: 8

Parent Publication: Open heart

Issue: 1

ISSN: 2053-3624